Advertisement
COO vs SYK
Which Stock Would AI Choose? The Cooper Companies (COO) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- The Cooper Companies (COO) delivered stronger recent revenue growth and earnings beats in its latest reported quarter compared to Stryker Corporation (SYK), which faced margin pressure from a cybersecurity incident.
- COO stock has outperformed the broader market on a year-to-date basis, while SYK has shown more modest gains amid sector headwinds.
- Both companies operate in the medical technology sector, with COO focused on vision care and women's health products and SYK emphasizing orthopedics and surgical solutions.
- SYK reaffirmed its full-year 2026 guidance despite Q1 challenges, whereas COO raised its annual outlook earlier in the year ahead of its upcoming earnings release.
- Market sentiment reflects caution for SYK following its recent 52-week low, contrasted with relatively steadier positioning for COO.
- Relative performance highlights trade-offs in growth momentum versus scale and diversification in the healthcare space.
Introduction
Investors and traders often compare stocks within the same sector to evaluate relative strength, valuation, and positioning amid evolving market conditions. The Cooper Companies (COO) and Stryker Corporation (SYK) both serve the medical technology industry but target distinct segments, making them relevant for those assessing healthcare exposure. This comparison examines recent financial results, stock behavior, and key contrasts to help market participants understand performance differences without favoring either name through wording alone.
COO Overview and Recent Performance
The Cooper Companies (COO) develops and markets contact lenses through its CooperVision unit and surgical and diagnostic products via CooperSurgical. In recent market activity, the stock posted a year-to-date return exceeding the S&P 500 benchmark, supported by solid demand for premium vision products. The company reported fiscal first-quarter 2026 results showing revenue growth of 6% and non-GAAP earnings per share (EPS) of $1.10, surpassing analyst expectations. Management had previously raised full-year 2026 revenue guidance, reflecting confidence in organic expansion. Upcoming second-quarter results, scheduled for early June 2026, represent a near-term catalyst as investors monitor execution against the updated outlook. Broader sentiment has remained constructive amid steady sector interest in healthcare innovation.
SYK Overview and Recent Performance
Stryker Corporation (SYK) provides medical devices and equipment focused on orthopedics, neurotechnology, and surgical technologies. Recent market activity showed the stock delivering modest year-to-date gains relative to the S&P 500, with performance tempered by operational disruptions. First-quarter 2026 results included revenue of $6.02 billion, up 2.6% year-over-year, though adjusted EPS missed consensus estimates due to a March cybersecurity incident that affected production and margins. The company reaffirmed its full-year 2026 guidance despite these pressures and noted ongoing recovery efforts. The shares reached a 52-week low during the period, reflecting investor caution. Leadership transitions, including a new president and chief operating officer (COO) effective earlier in the year, add another layer to the operational narrative in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed for various market conditions and strategies. Tickeron maintains hundreds of AI Trading Bots that analyze and trade thousands of different tickers, yet only the strongest performers suited to prevailing conditions earn placement in this section. The platform currently highlights its best AI Trending Bots, selected from a total of 351 available options, spanning multiple industries and trading styles. These bots feature differing approaches, timeframes, win rates, and performance statistics, allowing users to review detailed metrics before engaging. All available AI trading bots maintain distinct strategies and ticker focus areas. For additional details on current trending selections, visit Trending AI Robots.
Head-to-Head Comparison
In terms of business models, The Cooper Companies (COO) maintains a narrower focus on vision care and fertility-related offerings, while Stryker Corporation (SYK) offers broader exposure across orthopedics and surgical segments, providing greater scale but also more points of operational complexity. Recent momentum favors COO following stronger earnings beats and raised guidance, whereas SYK encountered margin compression from external factors despite reaffirming its annual targets. Growth drivers for COO center on premium product adoption, while SYK benefits from procedure volume recovery and potential acquisitions. Risk factors include execution on upcoming results for COO and ongoing recovery from the cybersecurity event for SYK. Sector exposure remains similar within healthcare, though market sentiment has shown more resilience for smaller-cap names like COO versus larger peers amid recent volatility.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, guidance trajectory, and relative price stability, Tickeron’s AI models would currently assign a modestly higher probability of favorable positioning to The Cooper Companies (COO) over Stryker Corporation (SYK). This assessment draws from stronger sequential growth signals and fewer near-term disruptions noted in available data. Outcomes remain probabilistic and depend on forthcoming results and broader market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Buy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 5 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а +7.75% price change this week, while SYK (@Medical/Nursing Services) price change was +8.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.10%. For the same industry, the average monthly price growth was +5.64%, and the average quarterly price growth was -8.37%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.65%. For the same industry, the average monthly price growth was -0.04%, and the average quarterly price growth was -13.16%.
Reported Earning Dates
COO is expected to report earnings on Sep 02, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+2.65% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| COO | SYK | COO / SYK | |
| Capitalization | 13.9B | 128B | 11% |
| EBITDA | 1.08B | 6.44B | 17% |
| Gain YTD | -13.348 | -5.081 | 263% |
| P/E Ratio | 55.44 | 35.27 | 157% |
| Revenue | 4.15B | 25.3B | 16% |
| Total Cash | 125M | 2.97B | 4% |
| Total Debt | 2.5B | 14.7B | 17% |
COO | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 58 | |
SMR RATING 1..100 | 86 | 57 | |
PRICE GROWTH RATING 1..100 | 51 | 59 | |
P/E GROWTH RATING 1..100 | 14 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for COO (72). This means that SYK’s stock grew somewhat faster than COO’s over the last 12 months.
SYK's Profit vs Risk Rating (58) in the Medical Specialties industry is somewhat better than the same rating for COO (100). This means that SYK’s stock grew somewhat faster than COO’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as COO (86). This means that SYK’s stock grew similarly to COO’s over the last 12 months.
COO's Price Growth Rating (51) in the Medical Specialties industry is in the same range as SYK (59). This means that COO’s stock grew similarly to SYK’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for SYK (81). This means that COO’s stock grew significantly faster than SYK’s over the last 12 months.
| COO | SYK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 52% | 1 day ago 60% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 59% |
| MACD ODDS (%) | N/A | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 49% | 1 day ago 46% |
| Advances ODDS (%) | 1 day ago 55% | 1 day ago 55% |
| Declines ODDS (%) | 12 days ago 60% | 17 days ago 53% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 50% | 5 days ago 51% |
Advertisement
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.